Loria-Rebolledo LE, Watson V, Hassan S, Gabbay M, Tahir N, Hossain M, Goodall M, Frith L. Public contributors' preferences for the organization of remote public involvement meetings in health and social care: a discrete choice experiment study. Health Expect. 2023 Feb;26(1):146-59. doi: 10.1111/hex.13641
Cunningham NA, Abhyankar P, Cowie J, Galinksy J, Methven K. Regenerative medicine: stroke survivor and carer views and motivations towards a proposed stem cell clinical trial using placebo neurosurgery. Health Expect. 2018 Feb;21(1):367-78. doi: 10.1111/hex.12632
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Edwards T, Cadigan RJ, Evans JP, Henderson GE. Biobanks containing clinical specimens: defining characteristics, policies, and practices. Clin Biochem. 2014 Mar;47(4-5):245-51. doi: 10.1016/j.clinbiochem.2013.11.023
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Cheraghi-Sohi S, Bower P, Mead N, McDonald R, Whalley D, Roland M. What are the key attributes of primary care for patients? Building a conceptual 'map' of patient preferences. Health Expect. 2006 Sep 1;9(3):275-84.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.